Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
The facility is expected to become operational by FY2028-29
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Nadda underlined that India’s policy framework is aligned with this transformation
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Subscribe To Our Newsletter & Stay Updated
